BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...to the U.S. and rebrands as a precision therapeutics...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...pressure from activist investor Velan Capital (see “Lantheus Enters Therapeutics with Progenics Takeout” ). Cancer precision therapeutics...
BioCentury | Apr 12, 2019
Company News

Helomics and Viome to study gut microbiome link to ovarian cancer

...and ovarian cancer to develop approaches to help doctors personalize treatment. The collaboration will utilize Helomics’...
...ovarian cancer treatment and investigate how those changes affect outcomes. Helomics Corp. is a subsidiary of Precision Therapeutics...
BioCentury | Nov 2, 2018
Targets & Mechanisms

Rethinking definitions of autoimmune disease

...Celsius and Scipher Medicine announced series A rounds this year, and aim to develop autoimmune precision therapeutics...
BioCentury | Jun 6, 2018
Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of...
BioCentury | May 18, 2018
Financial News

Third Rock leads $65M A round for Celsius

...Casdin Capital, Alexandria Venture Investments and undisclosed other investors. Celsius aims to discover and develop precision therapeutics...
BioCentury | May 15, 2018
Financial News

Third Rock leads $65M A round for Celsius

...Casdin Capital, Alexandria Venture Investments and undisclosed other investors. Celsius aims to discover and develop precision therapeutics...
BioCentury | Mar 30, 2018
Clinical News

Auris' Keyzilen misses in second Phase III tinnitus trial

...score, deterioration in hearing threshold and safety Status: Phase III data Milestone: NA Allison Johnson Keyzilen, esketamine (AM-101) Helomics Corp. NMDA...
BioCentury | Feb 2, 2018
Clinical News

Auris reports additional Phase III data of brimapitide for hearing loss

...baseline to day 28 Status: Additional Phase III data Milestone: Phase III data (1Q18) Jaime De Leon AM-111 brimapitide D-JNKI-1 XG-102 Helomics Corp. Xigen...
BioCentury | Dec 8, 2017
Company News

Skyline, Helomics, GLG partner for ovarian and breast cancer

...GLG Pharma LLC (Jupiter, Fla.), Skyline Medical Inc. (NASDAQ:SKLN) and Helomics Corp. (Pittsburgh, Pa.) partnered to develop...
...Streamway system to collect ascites fluids identified by GLG's Cell Capture, Culture and Screening system. Helomics...
...STAT3). Skyline and Helomics partnered in November to develop and commercialize Helomic's bioinformatic D-CHIP platform. Helomics Corp....
Items per page:
1 - 10 of 63
BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...to the U.S. and rebrands as a precision therapeutics...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...pressure from activist investor Velan Capital (see “Lantheus Enters Therapeutics with Progenics Takeout” ). Cancer precision therapeutics...
BioCentury | Apr 12, 2019
Company News

Helomics and Viome to study gut microbiome link to ovarian cancer

...and ovarian cancer to develop approaches to help doctors personalize treatment. The collaboration will utilize Helomics’...
...ovarian cancer treatment and investigate how those changes affect outcomes. Helomics Corp. is a subsidiary of Precision Therapeutics...
BioCentury | Nov 2, 2018
Targets & Mechanisms

Rethinking definitions of autoimmune disease

...Celsius and Scipher Medicine announced series A rounds this year, and aim to develop autoimmune precision therapeutics...
BioCentury | Jun 6, 2018
Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of...
BioCentury | May 18, 2018
Financial News

Third Rock leads $65M A round for Celsius

...Casdin Capital, Alexandria Venture Investments and undisclosed other investors. Celsius aims to discover and develop precision therapeutics...
BioCentury | May 15, 2018
Financial News

Third Rock leads $65M A round for Celsius

...Casdin Capital, Alexandria Venture Investments and undisclosed other investors. Celsius aims to discover and develop precision therapeutics...
BioCentury | Mar 30, 2018
Clinical News

Auris' Keyzilen misses in second Phase III tinnitus trial

...score, deterioration in hearing threshold and safety Status: Phase III data Milestone: NA Allison Johnson Keyzilen, esketamine (AM-101) Helomics Corp. NMDA...
BioCentury | Feb 2, 2018
Clinical News

Auris reports additional Phase III data of brimapitide for hearing loss

...baseline to day 28 Status: Additional Phase III data Milestone: Phase III data (1Q18) Jaime De Leon AM-111 brimapitide D-JNKI-1 XG-102 Helomics Corp. Xigen...
BioCentury | Dec 8, 2017
Company News

Skyline, Helomics, GLG partner for ovarian and breast cancer

...GLG Pharma LLC (Jupiter, Fla.), Skyline Medical Inc. (NASDAQ:SKLN) and Helomics Corp. (Pittsburgh, Pa.) partnered to develop...
...Streamway system to collect ascites fluids identified by GLG's Cell Capture, Culture and Screening system. Helomics...
...STAT3). Skyline and Helomics partnered in November to develop and commercialize Helomic's bioinformatic D-CHIP platform. Helomics Corp....
Items per page:
1 - 10 of 63